drugset / Trial / NCT00470821

Oral Melatonin in Critically Ill High-risk Patients

NCT00470821

Phase 4 Completed 96 enrolled University of Milan
RandomizedParallel-groupTriple-blindTreatment

Summary

Sleep disruptions are extremely common in high-risk critically ill patients. The investigators want to analyse oral melatonin potentialities as a sedative and a free-radicals scavenger for critically ill patients, and secondarily for preventing Delirium during their ICU stay and post-traumatic stress disorders after ICU discharge.

Timeline

Start
2007-05
Primary completion
2010-04
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Melatonin Small molecule 3 mg Oral

Indications

No indication recorded.